Perioperative Management of Antiplatelets
| Type of Procedure |
ASA |
ASA + Clopidogrel |
Comments |
| Minor procedures (dental,eye,skin) |
Continue |
Discontinue Clopidogrel 7-10 days prior |
2C |
| Elective non-cardiac surgery-low cardiac risk |
Discontinue 7-10 days prior |
Discontinue both 7-10 days prior |
2C |
| Elective non-cardiac surgery-high cardiac risk (exclusive of stents) |
Continue up to and beyond surgery |
Continue ASA , discontinue Clopidogrel if safe, resume 24 hrs after surgery (when there is adequate hemostasis) |
2C |
| Cardiac Surgery |
Continue ASA up to time of CABG, restart 6-48 hours after |
Discontinue Clopidogrel 5 days prior |
2C |
| Diagnostic procedures-low risk |
Continue |
Discontinue Clopidogrel 7-10 days prior to procedure |
2C |
| High risk |
Discontinue 7-10 days prior |
Discontinue both 7-10 days prior |
|
| Coronary stent- Elective |
|
Defer if < 6 weeks after BMS, < 6 months after DES |
1C |
| Coronary stent -Urgent |
|
BMS< 6 weeks continue both DES < 6 months continue both |
2C |
| Arthrocentesis |
Continue |
Discontinue Clopidogrel 7-10 days prior to procedure |
1C |
Prasugrel
Prasugrel is often used by cardiologists in the setting of clopidogrel failure. It is thought to inhibit close to 80% of platelet activity (whereas clopidogrel is in the range of 40-60%). Given this, the bleeding risk for prasugrel is greater than for clopidogrel and is therefore usually held 10 days prior to surgery.
ASA: Aspirin
CABG: Coronary artery bypass graft
BMS: Bare metal stent
DES: Drug-eluting stent
Strength of the Recommendations Grading System
Reference:
Perioperative Management of Antithrombotic Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141;e326S-350S.
Committee Members:
- Niren Angle, MD
- Ehtisham Mahmud, MD
- Gerard Manecke, MD
- Anushirvan Minokadeh, MD
- David Roth, MD, PhD
- Sam Tsimikas, MD
Updated July 2008